New psoriasis drug shows promise in early trial
NCT ID NCT03025542
First seen Mar 25, 2026 · Last updated May 21, 2026 · Updated 7 times
Summary
This study tested a new drug called bimekizumab in 49 adults with moderate to severe plaque psoriasis. The goal was to see how well it clears skin, how long it stays in the body, and if it is safe. Participants received the drug and were followed for 28 weeks to track changes in their psoriasis and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PLAQUE PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ps0016 101
Melbourne, Australia
-
Ps0016 102
Kogarah, Australia
-
Ps0016 104
Woolloongabba, Australia
-
Ps0016 201
Ajax, Canada
-
Ps0016 202
Windsor, Canada
-
Ps0016 203
London, Canada
-
Ps0016 501
Chisinau, Moldova
-
Ps0016 704
Bexley, Ohio, United States
Conditions
Explore the condition pages connected to this study.